Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)
- Conditions
- Metastatic Non Small Cell Lung Cancer
- Interventions
- Registration Number
- NCT05555732
- Lead Sponsor
- Daiichi Sankyo
- Brief Summary
This study is designed to assess the efficacy and safety of datopotamab deruxtecan (Dato-DXd) in combination with pembrolizumab versus pembrolizumab in combination with pemetrexed and platinum chemotherapy in participants with no prior therapy for advanced or metastatic non-squamous non-small cell lung cancer (NSCLC).
- Detailed Description
The primary objectives of the study are Progression Free Survival (PFS) and Overall Survival (OS) as first line therapy in participants with programmed death-ligand 1 (PD-L1) TPS \<50% and advanced or metastatic NSCLC without actionable genomic alternations.
Eligible participants will be randomized in a 1:1:1 ratio to a) Dato-DXd plus pembrolizumab plus platinum; b) Dato-DXd plus pembrolizumab; or c) pembrolizumab plus pemetrexed plus platinum. Platinum therapy will be either carboplatin or cisplatin at investigator discretion. The study will be divided into three periods: Screening Period (including tissue screening), Treatment Period, and Follow-up Period.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 1170
- Sign and date the Main ICF, prior to the start of any study- specific qualification procedures. Is willing and able to comply with scheduled visits, drug administration plan, laboratory tests, other study procedures, and study restrictions.
- Adults ≥18 at the time the Main ICF is signed. (Follow local regulatory requirements if the legal age of adult voluntary consent for study participation is >18 years old).
- Has tumor with PD-L1 TPS <50% as determined by PD-L1 IHC 22C3 pharmDx assay by central testing (minimum of six slides). PD-L1 expression results available at the same central laboratory from screening for the purpose of entry into another Dato-DXd study may be used for tissue screening purposes in this study as long as the subject has not been randomized/enrolled in the other study.
- Has provided a formalin-fixed tumor tissue sample (minimum of 4 × 4-micron sections or block equivalent) for the measurement of TROP2 protein expression and for the assessment of other exploratory biomarkers. This tissue requirement is in addition to the tissue required for PD-L1 testing for tissue screening purposes. If a documented law or regulation prohibits (or does not approve) sample collection, then such sample will not be collected, and the subject is still eligible for the study.
- Has not been treated with systemic anticancer therapy for advanced or metastatic non-squamous NSCLC. Subjects who received adjuvant or neoadjuvant therapy other than those listed in the exclusion criteria are eligible if the adjuvant/ neoadjuvant therapy was completed at least 6 months prior to the diagnosis of advanced/metastatic disease and should not have progressed on or within the 6 months of completion.
- Has measurable disease based on local imaging assessment using RECIST v1.1; radiographic tumor assessment must be performed within 28 days before randomization.
Key
-
Has received prior systemic treatment for advanced/metastatic NSCLC.
-
Has received prior treatment with any of the following, including in the adjuvant/neoadjuvant setting (for NSCLC):
- Any agent, including an ADC, containing a chemotherapeutic agent targeting topoisomerase I
- TROP2-targeted therapy
- Any anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (eg, CTLA-4, OX40, CD137)
- Any other ICIs Subjects who received adjuvant or neoadjuvant therapy OTHER than those listed above are eligible if the adjuvant/neoadjuvant therapy was completed at least 6 months prior to the diagnosis of advanced or metastatic disease.
-
Has received a live vaccine within 30 days prior to the first dose of study treatment.
Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacillus Calmette-Guérin (BCG), and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (eg, FluMist®) are live attenuated vaccines and are not allowed. For any subject receiving an approved severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) vaccine, please follow the vaccine label and/or local guidance. The vaccine manufacturer and the date of administration should be recorded on the electronic case report form (Concomitant Medications page), as should any AEs relating to the vaccine (including hypersensitivity or allergies). Note: Any licensed SARS-CoV2 vaccine (including those authorized for emergency use) in a particular country is allowed in the study as long as the vaccine is an mRNA vaccine, replication-incompetent adenoviral vaccine, or inactivated vaccine. Such vaccines will be treated just as any other concomitant therapy.
Investigational vaccines (ie, those not licensed or authorized for emergency use) are not allowed.
-
Has spinal cord compression or clinically active untreated CNS metastases and/or carcinomatous meningitis. Subjects with previously treated brain metastases may participate provided they are radiologically stable (ie, without evidence of progression) for at least 2 weeks by repeat imaging (Note: Repeat imaging should be performed during study screening), clinically stable, and without requirement of steroid treatment for at least 7 days before the first dose of study drug. Note: A contrasted computed tomography (CT) scan or magnetic resonance imaging (MRI) scan of the brain at baseline (MRI with contrast preferred) is required for all subjects. For those subjects in whom CNS metastases are first discovered at the time of screening, the treating investigator must delay of study treatment to document stability of CNS metastases with repeat imaging at least 2 weeks later (in which case, repeat of all screening activity may be required).
-
Has uncontrolled or significant cardiovascular disease not controlled by maximal medical therapy, including:
- Mean QT interval corrected for heart rate using Fridericia's formula (QTcF) interval >470 msec regardless of sex (based on the 12-lead electrocardiogram [ECG] performed at screening).
- Myocardial infarction within 6 months prior to Cycle 1 Day 1.
- History of a serious cardiac arrhythmia requiring treatment
- Uncontrolled angina pectoris within 6 months prior to Cycle 1 Day 1.
- Left ventricular ejection fraction (LVEF) <50% by echocardiogram (ECHO) or multigated acquisition (MUGA) scan within 28 days before randomization.
- New York Heart Association (NYHA) Class II-IV congestive heart failure (CHF) at screening. Subjects with a history of Class II to IV CHF prior to screening, must have returned to Class I CHF and have LVEF ≥50% (by either an ECHO or MUGA scan within 28 days before randomization) in order to be eligible.
- Uncontrolled hypertension (resting systolic blood pressure >180 mmHg or diastolic blood pressure >110 mmHg within 28 days before randomization that is not resolved despite maximal medical therapy).
-
Clinically severe pulmonary compromise as judged by the investigator resulting from intercurrent pulmonary illnesses including, but not limited to, any underlying pulmonary disorder (eg, pulmonary emboli diagnosed within 3 months of Cycle 1 Day 1, severe asthma, severe chronic obstructive pulmonary disease, restrictive lung disease, pleural effusion, etc) or any autoimmune, connective tissue or inflammatory disorders with pulmonary involvement (eg, rheumatoid arthritis, Sjögren's syndrome, sarcoidosis, etc), or prior complete pneumonectomy.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Dato-DXd + Pembrolizumab + Platinum Chemotherapy Datopotamab Deruxtecan Participants will be randomized to receive 6.0mg/kg Dato-DXd plus 200 mg pembrolizumab plus platinum chemotherapy (cisplatin 75 mg/m\^2 or carboplatin area under the curve \[AUC) 5\]). Dato-DXd + Pembrolizumab + Platinum Chemotherapy Pembrolizumab Participants will be randomized to receive 6.0mg/kg Dato-DXd plus 200 mg pembrolizumab plus platinum chemotherapy (cisplatin 75 mg/m\^2 or carboplatin area under the curve \[AUC) 5\]). Dato-DXd + Pembrolizumab + Platinum Chemotherapy Carboplatin Participants will be randomized to receive 6.0mg/kg Dato-DXd plus 200 mg pembrolizumab plus platinum chemotherapy (cisplatin 75 mg/m\^2 or carboplatin area under the curve \[AUC) 5\]). Dato-DXd + Pembrolizumab + Platinum Chemotherapy Cisplatin Participants will be randomized to receive 6.0mg/kg Dato-DXd plus 200 mg pembrolizumab plus platinum chemotherapy (cisplatin 75 mg/m\^2 or carboplatin area under the curve \[AUC) 5\]). Dato-DXd + Pembrolizumab Datopotamab Deruxtecan Participants will be randomized to receive 6.0mg/kg Dato-DXd plus 200 mg pembrolizumab. Dato-DXd + Pembrolizumab Pembrolizumab Participants will be randomized to receive 6.0mg/kg Dato-DXd plus 200 mg pembrolizumab. Pembrolizumab + Pemetrexed + Platinum Chemotherapy Pembrolizumab Participants will be randomized to receive 200 mg pembrolizumab plus 500 mg/m\^2 pemetrexed plus platinum chemotherapy (cisplatin 75 mg/m\^2 or carboplatin area under the curve \[AUC) 5\]). Pembrolizumab + Pemetrexed + Platinum Chemotherapy Pemetrexed Participants will be randomized to receive 200 mg pembrolizumab plus 500 mg/m\^2 pemetrexed plus platinum chemotherapy (cisplatin 75 mg/m\^2 or carboplatin area under the curve \[AUC) 5\]). Pembrolizumab + Pemetrexed + Platinum Chemotherapy Carboplatin Participants will be randomized to receive 200 mg pembrolizumab plus 500 mg/m\^2 pemetrexed plus platinum chemotherapy (cisplatin 75 mg/m\^2 or carboplatin area under the curve \[AUC) 5\]). Pembrolizumab + Pemetrexed + Platinum Chemotherapy Cisplatin Participants will be randomized to receive 200 mg pembrolizumab plus 500 mg/m\^2 pemetrexed plus platinum chemotherapy (cisplatin 75 mg/m\^2 or carboplatin area under the curve \[AUC) 5\]).
- Primary Outcome Measures
Name Time Method Overall Survival in Participants in Participants With Advanced or Metastatic Non Small Cell Lung Cancer (NSCLC) From randomization until disease progression or death (whichever occurs first), up to approximately 57 months Overall Survival (OS) is defined as the time from randomization to death due to any cause.
Progression-free Survival Based on Blinded Independent Central Review in Participants With Advanced or Metastatic Non Small Cell Lung Cancer (NSCLC) From randomization until disease progression or death (whichever occurs first), up to approximately 29 months Progression-free Survival (PFS) is defined as the time from randomization to the first documented radiographic disease progression or death due to any cause, whichever occurs first, assessed by blinded independent central review (BICR) per Response Evaluation Criteria in Solid Tumors (RECIST), Version 1.1.
- Secondary Outcome Measures
Name Time Method Disease Control Rate by BICR and Investigator in Participants With Advanced or Metastatic Non Small Cell Lung Cancer (NSCLC) From randomization until disease progression or death (whichever occurs first), up to approximately 29 months Disease Control Rate (DCR) is defined as the proportion of participants who achieved a BOR of confirmed CR, confirmed PR, or stable disease (SD), assessed by BICR and by the Investigator per RECIST Version 1.1.
Objective Response Rate by Blinded Independent Central Review in Participants With Advanced or Metastatic Non Small Cell Lung Cancer (NSCLC) From randomization until disease progression or death (whichever occurs first), up to approximately 29 months Objective Response Rate (ORR) is defined as the proportion of participants who achieved a best overall response (BOR) of confirmed complete response (CR) or confirmed partial response (PR), assessed by BICR per RECIST Version 1.1.
Progression-free Survival by Investigator in Participants With Advanced or Metastatic Non Small Cell Lung Cancer (NSCLC) From randomization until disease progression or death (whichever occurs first), up to approximately 29 months Progression-free Survival (PFS) is defined as the time from randomization to the first documented radiographic disease progression or death due to any cause, whichever occurs first, assessed by the Investigator per RECIST Version 1.1.
Progression-free Survival 2 in Participants With Advanced or Metastatic Non Small Cell Lung Cancer (NSCLC) From randomization until disease progression or death (whichever occurs first), up to approximately 57 months Progression-free Survival 2 (PFS2) is defined as the time from randomization to the first documented radiographic disease progression or death due to any cause, whichever occurs first, assessed by local standard clinical practice
Duration of Response by BICR and Investigator in Participants With Advanced or Metastatic Non Small Cell Lung Cancer (NSCLC) From date of first objective response (CR or PR) to date of first radiographic disease progression or death due to any cause (whichever occurs first), up to approximately 29 months Duration of Response (DoR) is defined as the time from the date of the first documentation of objective response (confirmed CR or confirmed PR) to the date of the first radiographic disease progression or death due to any cause, whichever occurs first, assessed by BICR and by the Investigator per RECIST Version 1.1.
Time to Response by BICR and Investigator in Participants With Advanced or Metastatic Non Small Cell Lung Cancer (NSCLC) From randomization to date of first objective response (CR or PR), up to approximately 29 months Time to Response (TTR) is defined as the time from randomization to the date of the first documentation of objective response (confirmed CR or confirmed PR) in responding participants, assessed by BICR and by the Investigator per RECIST Version 1.1.
Objective Response Rate by Investigator in Participants With Advanced or Metastatic Non Small Cell Lung Cancer (NSCLC) From randomization until disease progression or death (whichever occurs first), up to approximately 29 months Objective Response Rate (ORR) is defined as the proportion of participants who achieved a best overall response (BOR) of confirmed complete response (CR) or confirmed partial response (PR), assessed by the Investigator per RECIST Version 1.1.
Proportion of Participants Who Are Anti-Drug Antibody (ADA)-Positive (Baseline and Post-Baseline) and Proportion of Participants Who Have Treatment-emergent ADA Baseline and up to 57 months The immunogenicity of Dato-DXd in combination with pembrolizumab will be assessed.
Time to Deterioration in Participants With Advanced or Metastatic Non Small Cell Lung Cancer (NSCLC) From randomization until disease progression or death (whichever occurs first), up to approximately 57 months Time to Deterioration (TTD) is defined as the time from randomization to first onset of a ≥10-point increase in cough, chest pain, or dyspnea, confirmed by a second adjacent ≥10-point increase from randomization in the same symptom, or confirmed by death within 21 days of a ≥10-point increase from randomization, assessed the European Organization for Research and Treatment of Cancer Lung cancer module (EORTC-QLQ-LC13).
Number of Participants With Treatment-emergent Adverse Events (TEAE) in Participants With Advanced or Metastatic Non Small Cell Lung Cancer (NSCLC) Up to 57 months A TEAE is defined as an AE with a start or worsening date on or after the start date of study treatment until 37 days after the end date of study treatment.
Trial Locations
- Locations (239)
Flinders Medical Centre (Fmc)
🇦🇺Bedford Park, Australia
Santa Casa de Misericordia de Porto Alegre
🇧🇷Porto Alegre, Brazil
Instituto Nacional de Că'Ncer - Inca
🇧🇷Rio de Janeiro, Brazil
Evangelische Lungenklinik Berlin
🇩🇪Berlin, Germany
Klinikum Chemnitz
🇩🇪Chemnitz, Germany
Universitaetsklinikum Essen
🇩🇪Essen, Germany
Klinikum Esslingen Gmbh
🇩🇪Esslingen, Germany
Universitaetsklinikum Freiburg
🇩🇪Freiburg, Germany
University Hospital Giessen, ZIM IV
🇩🇪Giessen, Germany
External pharmacy Fortuna Herstellung GmbH of main site Universitaetsmedizin Mannheim
🇩🇪Mannheim, Germany
University Hospital Mă Nster
🇩🇪Muenster, Germany
Ludwig-Maximilians University Hospital of Munich
🇩🇪Munich, Germany
Sotiria General Hospital of Chest Diseases
🇬🇷Athens, Greece
University General Hospital of Heraklion
🇬🇷Heraklion, Greece
University Hospital of Ioannina Uhi
🇬🇷Ioannina, Greece
Centro de Investigacion Clinica de Oaxaca CICLO
🇲🇽Oaxaca, Mexico
Amphia Ziekenhuis
🇳🇱Breda, Netherlands
Leiden University Medical Center
🇳🇱Leiden, Netherlands
Jeroen Bosch Ziekenhuis Jbz
🇳🇱s-Hertogenbosch, Netherlands
II Klinika Chorob Pluc i Gruzlicy
🇵🇱Bialystok, Poland
Centrum Terapii Wspolczesnej
🇵🇱Lodz, Poland
Instytut Centrum Zdrowia Matki Polki (Iczmp)
🇵🇱Lodz, Poland
SPSK4, Samodzielny Publiczny Szpital Kliniczny Nr 4 w Lublinie
🇵🇱Lublin, Poland
Hospital Universitario Fundacion Jimenez Diaz
🇪🇸Madrid, Spain
Hospital Regional Universitario Malaga
🇪🇸Malaga, Spain
CHUO
🇪🇸Ourense, Spain
Hosp Univ Virgen Macarena
🇪🇸Sevilla, Spain
Hospital Universitario Virgen de Valme
🇪🇸Sevilla, Spain
Hospital Universitario y Politecnico de La Fe
🇪🇸Valenica, Spain
Hospital Universitario Miguel Servet
🇪🇸Zaragoza, Spain
Hôpital Foch
🇫🇷Suresnes, France
Southern Cancer Center Pc
🇺🇸Daphne, Alabama, United States
Ironwood Cancer and Research Centers
🇺🇸Chandler, Arizona, United States
Arizona Oncology Associates, Pc - Nahoa
🇺🇸Prescott Valley, Arizona, United States
Hoag Memorial Hospital Prebyterian
🇺🇸Newport Beach, California, United States
Compassionate Cancer Care Medical Group
🇺🇸Riverside, California, United States
Sansum Clinic
🇺🇸Santa Barbara, California, United States
Ronald Reagan UCLA Medical Center
🇺🇸Santa Monica, California, United States
UCHealth Memorial Hospital
🇺🇸Colorado Springs, Colorado, United States
Florida Cancer Specialists - South
🇺🇸Fort Myers, Florida, United States
Cancer Specialist of North Florida
🇺🇸Jacksonville, Florida, United States
Cancer Care Centers of Brevard, Inc.
🇺🇸Palm Bay, Florida, United States
Woodlands Medical Specialists, Pa
🇺🇸Pensacola, Florida, United States
Florida Cancer Specialists-North
🇺🇸Saint Petersburg, Florida, United States
Emory University - Winship Cancer Institute Wci
🇺🇸Atlanta, Georgia, United States
Illinois Cancer Specialists
🇺🇸Niles, Illinois, United States
American Oncology Partners of Maryland
🇺🇸Bethesda, Maryland, United States
Maryland Oncology Heamtology P.A.
🇺🇸Columbia, Maryland, United States
Beth Israel Deaconess Medical Center
🇺🇸Boston, Massachusetts, United States
Dana Farber Cancer Institute; Inv Drg Svc Pharm
🇺🇸Boston, Massachusetts, United States
Dana Farber Cancer Institute At St. Elizabeth'S Medical Center
🇺🇸Brighton, Massachusetts, United States
Dana Farber Brigham Cancer Center
🇺🇸Foxboro, Massachusetts, United States
Dana Farber At Milford Regional Cancer Center
🇺🇸Milford, Massachusetts, United States
Dana Farber/Bwcc in Affiliation With South Shore Hospital
🇺🇸South Weymouth, Massachusetts, United States
Astera Cancer Care
🇺🇸East Brunswick, New Jersey, United States
Regional Cancer Care Associates LLC
🇺🇸Hackensack, New Jersey, United States
North Shore Hematology Oncology Associates dba NY Cancer and Blood Specialists - Bronx
🇺🇸Bronx, New York, United States
North Shore Hematology Oncology Associates dba NY Cancer and Blood Specialists- New Hyde Park
🇺🇸New Hyde Park, New York, United States
North Shore Hematology Oncology Associates
🇺🇸Patchogue, New York, United States
North Shore Hematology Oncology Associates DBA NY Cancer and Blood Specialists
🇺🇸Port Jefferson Station, New York, United States
Texas Oncology, P.A.
🇺🇸Sugar Land, Texas, United States
Ut Health San Antonio
🇺🇸San Antonio, Texas, United States
Texas Oncology-Tyler
🇺🇸Tyler, Texas, United States
Utah Cancer Specialists IHO Corp
🇺🇸Salt Lake City, Utah, United States
Providence Regional Cancer System
🇺🇸Lacey, Washington, United States
VA Puget Sound Health Care System
🇺🇸Seattle, Washington, United States
Instituto Alexander Fleming
🇦🇷Ciudad Autonoma de Buenos Aires, Argentina
Fundacion CENIT para la investigacion en Neurociencias
🇦🇷Ciudad Autonoma de Buenos Aire, Argentina
Hospital de La Comunidad
🇦🇷Mar del Plata, Argentina
Centro de Investigacion Pergamino Sa
🇦🇷Pergamino, Argentina
Instituto de Oncologia de Rosario
🇦🇷Rosario, Argentina
Sanatorio Parque
🇦🇷Rosario, Argentina
Centro Polivalente de Asistencia E Investigacion Clinica Cer San Juan
🇦🇷San Juan, Argentina
Centro de Investigaciones Clinicas. Clinica Viedma S.A.
🇦🇷Viedma, Argentina
CRSA/ St Andrews Hospital
🇦🇺Adelaide, Australia
PSEHOG (Peninsula and South Eastern Haematology and Oncology Group)
🇦🇺Frankston, Australia
St George Public Hospital
🇦🇺Kogarah, Australia
Southern Medical Day Care Centre
🇦🇺Wollongong, Australia
Princess Alexandra Hospital
🇦🇺Woolloongabba, Australia
Landeskrankenhaus Feldkirch
🇦🇹Feldkirch, Austria
Klinikum Klagenfurt Pulmologie
🇦🇹Klagenfurt, Austria
Karl Landsteiner Institut Fã¼R Lungenforschung Und Pneumologische Onkologie C/O Klinik Floridsdorf
🇦🇹Vienna, Austria
Az Maria Middelares - Campus Maria Middelares
🇧🇪Gent, Belgium
Centre hospitalier Jolimont-Lobbes
🇧🇪Haine Saint-Paul, Belgium
Jessa Hospital
🇧🇪Hasselt, Belgium
Cliniques Saint Pierre Ottignies (CSPO)
🇧🇪Ottignies, Belgium
Az Nikolaas
🇧🇪Sint-Niklaas, Belgium
Personal Oncologia de Precisao - Cenantron
🇧🇷Belo Horizonte, Brazil
Fundaco Universidade de Caxias Do Sul- Instituto de Pesquisas Em Saude Ips-Ucs
🇧🇷Caxias do Sul, Brazil
Hospital Erasto Gaertner
🇧🇷Curitiba, Brazil
Oncosite - Centro de Pesquisa Clinica Em Oncologia Ltda
🇧🇷Ijui, Brazil
Clínica de Neoplasias Litoral Ltda
🇧🇷ItajaĂ-, Brazil
Clnica Lacks
🇧🇷Pelotas, Brazil
Centro de Estudos E Pesquisa de Hematologia E Oncologia - Cepho
🇧🇷Santo Andre, Brazil
Instituto de Ensino E Pesquisa Sao Lucas
🇧🇷Sao Paulo, Brazil
Instituto Do Cancer Brasil - Unidade Taubate
🇧🇷Taubate, Brazil
CHU de Quebec -Universite Laval Hopital de L'Enfant-Jesus
🇨🇦Quebec City, Canada
Centro de Estudios Clinicos Saga Spa
🇨🇱Santiago de Chile, Chile
ONCOVIDA
🇨🇱Santiago, Chile
Orlandi Oncologia
🇨🇱Santiago, Chile
Centro de Investigaciones Clinicas Vina Del Mar
🇨🇱ViĂąa Del Mar, Chile
Peking University Cancer Hospital Beijing Cancer Hospital Beijing Institute For Cancer Research
🇨🇳Beijing Sheng, China
Peking University Peoples Hospital
🇨🇳Beijing, China
Cangzhou Peoples Hospital
🇨🇳Cangzhou, China
First Affiliated Hospital of Medical College of Jilin University
🇨🇳Changchun, China
Jilin Cancer Hospital
🇨🇳Changchun, China
Hunan Cancer Hospital
🇨🇳Changsha, China
University of Electronic Science Technology of China UESTC - Sichuan Cancer Hospital Institute SIC
🇨🇳Chengdu, China
Chongqing University Cancer Hospital
🇨🇳Chongqing, China
Fujian Medical University - Union Hospital Foochow Christian Union Hospital
🇨🇳Fuzhou, China
The First Affiliated Hospital Sun Yat-Sen University
🇨🇳Guangzhou, China
Affiliated Cancer Hospital and Insititute of Guangzhou Medical University
🇨🇳Guangzhou, China
The First Affiliated Hospital of Guangzhou Medical University
🇨🇳Guangzhou, China
Run Run Shaw Hospital, Zhejiang University School of Medicine
🇨🇳Hangzhou, China
The First Affiliated Hospital of College of Medicine Zhejiang University
🇨🇳Hangzhou, China
Harbin Medical University Cancer Hospital
🇨🇳Harbin, China
Inner Mongolia Medical University- the Affiliated Hospital
🇨🇳Hohhot, China
Jiamusi Cancer Hospital
🇨🇳Jiamusi, China
Linyi Cancer Hospital
🇨🇳Linyi, China
The First Affiliated Hospital of Nanchang University
🇨🇳Nanchang, China
Zhongda Hospital, Southeast University
🇨🇳Nanjing, China
Shanghai Chest Hospital
🇨🇳Shanghai, China
Fudan University Shanghai Cancer Center
🇨🇳Shanghai, China
Liaoning Cancer Hospital & Institute
🇨🇳Shenyang, China
Union Hospital of Tongji Medical College Huazhong University of Science and Technology
🇨🇳Wuhan, China
The First Affiliate Hospital of Xi'An Jiaotong University
🇨🇳Xi'an, China
Xiangyang Central Hospital
🇨🇳Xianyang, China
Henan Cancer Hospital
🇨🇳Zhengzhou, China
The First Affiliated Hosptial of Xinjiang Medical University
🇨🇳Ürümqi, China
FN Brno Klinika Nemoci Plicnich a TBC
🇨🇿Brno, Czechia
Fakultni nemocnice Olomouc FNOL
🇨🇿Olomouc, Czechia
Hopital Jean Minjoz - CHU de Besancon
🇫🇷Besancon, France
Chu de Bordeaux - Hopital Saint Andre
🇫🇷Bordeaux, France
Centre Hospitalier Universitaire, CHU, de Poitiers
🇫🇷France, France
Hopital Lyon Sud
🇫🇷Lyon, France
Centre Leon Berard
🇫🇷Lyon, France
Aphm - Hopital Nord
🇫🇷Marseille Cedex 20, France
Institut Paoli Calmettes
🇫🇷Marseille, France
Chu de Montpellier
🇫🇷Montpellier Cedex 5, France
Chu de Nantes
🇫🇷Nantes, France
Hopital Prive Du Confluent
🇫🇷Nantes, France
Institut Curie
🇫🇷Paris Cedex 05, France
Tenon Hospital
🇫🇷Paris, France
CHU de Rennes - Hopital Pontchaillou
🇫🇷Rennes, France
Metropolitan Hospital
🇬🇷Neo Faliro, Greece
Olympion Hospital
🇬🇷Patras, Greece
Euromedica General Clinic of Thessaloniki
🇬🇷Thessaloniki, Greece
Bioclinic Thessaloniki (Galinos Clinic)
🇬🇷Thessalonki, Greece
Tuen Mun Hospital
🇭🇰Hong Kong, Hong Kong
Prince of Wales Hospital / The Chinese University of Hong Kong
🇭🇰Hong Kong, Hong Kong
Queen Mary Hospital
🇭🇰Pok Fu Lam, Hong Kong
National Koranyi Institute For Pulmonology
🇭🇺Budapest, Hungary
Veszprem Megyei Tudogyogyintezet Farkasgyepu
🇭🇺Farkasgyepu, Hungary
Bkmk Hospital
🇭🇺KecskemĂŠt, Hungary
Fejer Megyei Szent Gyorgy Korhaz Pulmonologiai Osztaly
🇭🇺Szekesfehervar, Hungary
Hetenyi G Korhaz, Onkologiai Kozpont
🇭🇺Szolnok, Hungary
Istituto Di Candiolo Irccs
🇮🇹Candiolo, Italy
Ospedale San Luca
🇮🇹Lucca, Italy
Azienda Ospedaliero - Universitaria San Luigi Gonzaga
🇮🇹Orbassano, Italy
IFO Regina Elena
🇮🇹Rome, Italy
Ospedale S. Maria Della Misericordia
🇮🇹Udine, Italy
Asst Sette Laghi
🇮🇹Varese, Italy
Azienda Ospedaliera Universitaria Integrata Verona Ospedale Borgo Roma Crc - Centro Ricerche Clinich
🇮🇹Verona, Italy
NHO Shikoku Cancer Center
🇯🇵Ehime, Japan
Kurume University Hospital
🇯🇵Fukoka, Japan
Kyushu Cancer Center
🇯🇵Fukuoka, Japan
Kyushu University Hospital
🇯🇵Fukuoka, Japan
Teine Keijinkai Hospital
🇯🇵Hokkaido, Japan
Hyogo Medical University Hospital
🇯🇵Hyogo, Japan
Kanazawa University Hospital
🇯🇵Ishikawa, Japan
Kanagawa Cancer Center
🇯🇵Kanagawa, Japan
Kitasato University hospital
🇯🇵Kanagawa, Japan
Social Welfare Organization Saiseikai Imperial Gift Foundation, Inc. Saiseikai Kumamoto Hospital
🇯🇵Kumamoto, Japan
University Hospital Kyoto Prefectual University of Medicine
🇯🇵Kyoto, Japan
Matsusaka Municipal Hospital
🇯🇵Mie, Japan
Sendai Kousei Hospital
🇯🇵Miyagi, Japan
Niigata Cancer Center Hospital
🇯🇵Niigata, Japan
Osaka International Cancer Institute
🇯🇵Osaka, Japan
Osaka Toneyama Medical Center
🇯🇵Osaka, Japan
Kansai Medical University Hospital
🇯🇵Osaka, Japan
NHO Kinki-Chuo Chest Medical Center
🇯🇵Osaka, Japan
Dokkyo Medical University Hospital
🇯🇵Tochigi, Japan
Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital
🇯🇵Tokyo, Japan
Juntendo University Hospital
🇯🇵Tokyo, Japan
The Cancer Institute Hospital of JFCR
🇯🇵Tokyo, Japan
Toho University Omori Medical Center
🇯🇵Tokyo, Japan
Iwakuni Clinical Center
🇯🇵Yamaguchi, Japan
Yamaguchi-Ube Medical Center
🇯🇵Yamaguchi, Japan
Yamanashi Prefectural Central Hospital
🇯🇵Yamanashi, Japan
Chungbuk National University Hospital
🇰🇷Cheongjusi, Korea, Republic of
Kyungpook National University Chilgok Hospital
🇰🇷Daegu, Korea, Republic of
Samsung Medical Center
🇰🇷Gangnam-Gu, Korea, Republic of
National Cancer Center
🇰🇷Goyang-si, Korea, Republic of
Gyeongsang National University Hospital
🇰🇷Jinju-si Gyeongsangnam-do, Korea, Republic of
Seoul National University Bundang Hospital
🇰🇷Seongnam-si, Korea, Republic of
Asan Medical Center
🇰🇷Seoul, Korea, Republic of
Yonsei University Health System - Severance Hospital
🇰🇷Seoul, Korea, Republic of
The Catholic Univ. of Korea, Seoul St. Marys Hospital
🇰🇷Seoul, Korea, Republic of
Cryptex Investigacion Clinica Sa de Cv
🇲🇽Cuauhtemoc, Mexico
Hospital Civil de Guadalajara Fray Antonio Alcalde
🇲🇽Guadalajara, Mexico
Med Polonia Sp. Z O.O.
🇵🇱Poznan, Poland
Maria Sklodowska-Curie National Research Institute of Oncology
🇵🇱Warszawa, Poland
Fundacao Champalimaud
🇵🇹Lisbon, Portugal
IPO Porto Francisco Gentil, E.P.E.
🇵🇹Porto, Portugal
Institute of Oncology Prof. Dr. Ion Chiricuta
🇷🇴Cluj- Napoca, Romania
Onco Clinic Consult Sa
🇷🇴Craiova, Romania
Centrul de Oncologie Sfantu Nectarie
🇷🇴Craiova, Romania
Oncocenter Oncologie Clinica S.R.L
🇷🇴Timisoara, Romania
Vall Hebron University Hospital
🇪🇸Barcelona, Spain
Hospital Clinic I Provincial de Barcelona
🇪🇸Barcelona, Spain
Hospital Universitario Arnau de Vilanova
🇪🇸Lleida, Spain
Hospital General Universitario Gregorio Marañon
🇪🇸Madrid, Spain
Hospital Clinico San Carlos
🇪🇸Madrid, Spain
Kantonsspital Baselland
🇨🇭Liestal, Switzerland
Kantonsspital St. Gallen
🇨🇭St. Gallen, Switzerland
Spital Sts Ag
🇨🇭Thun, Switzerland
Changhua Christian Hospital
🇨🇳Changhua, Taiwan
China Medical University Hospital
🇨🇳Hsia, Taiwan
Taichung Veterans General Hospital
🇨🇳Taichung, Taiwan
National Cheng Kung University Hospital
🇨🇳Tainan, Taiwan
National Taiwan University Hospital
🇨🇳Taipei, Taiwan
Koo Foundation Sun Yat-Sen Cancer Center
🇨🇳Taipei, Taiwan
Taipei Veterans General Hospital
🇨🇳Taipei, Taiwan
Tri-Service General Hospital
🇨🇳Taipei, Taiwan
Linkou Chang Gung Memorial Hospital
🇨🇳Taoyuan, Taiwan
Faculty of Medicine Chulalongkorn University
🇹🇭Bangkok, Thailand
Ramathibodi Hospital
🇹🇭Bangkok, Thailand
Siriraj Hospital
🇹🇭Bangkok, Thailand
Chiang Mai University CMU - Maharaj Nakhon Chiang Mai Hospital Nakorn Chiang Mai Hospital
🇹🇭Chiang Mai, Thailand
Prince of Songkla University PSU - Faculty of Medicine
🇹🇭Hat Yai, Thailand
Khon Kaen University - Faculty of Medicine-Srinagarind Hospital
🇹🇭Mueang Nonthaburi, Thailand
Baskent University
🇹🇷Adana, Turkey
Ankara Bilkent City Hospital
🇹🇷Ankara, Turkey
Akdeniz University Hospital
🇹🇷Antalya, Turkey
Medipol Mega University Hospital
🇹🇷Bağcılar, Turkey
Memorial Ankara Hospital
🇹🇷Cankaya/Ankara, Turkey
Istanbul Medeniyet University Medical Faculty
🇹🇷Istanbul, Turkey
Adana Acibadem Hospital
🇹🇷Seyhan, Turkey
Barts Health NHS Trust
🇬🇧London, United Kingdom